Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Employees - 131,
CEO - Dr. Robert Alexander Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 28.86M
Altman ZScore(max is 10): -20.13, Piotroski Score(max is 10): 1, Working Capital: $67802000, Total Assets: $96601000, Retained Earnings: $-1234295000, EBIT: -118761000, Total Liabilities: $17784000, Revenue: $0
AryaFin Target Price - $0.15 - Current Price $0.32 - Analyst Target Price $0.34
| Ticker | ALLK |
| Index | - |
| Curent Price | 0.32 |
| Change | -0.40% |
| Market Cap | 28.86M |
| Average Volume | 2.77M |
| Income | -115.82M |
| Sales | 0.00M |
| Book Value/Share | 0.88 |
| Cash/Share | 0.91 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 61 |
| Moving Avg 20days | 26.52% |
| Moving Avg 50days | 7.37% |
| Moving Avg 200days | -57.73% |
| Shares Outstanding | 89.65M |
| Earnings Date | Mar 12 AMC |
| Inst. Ownership | 78.56% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 0.36 |
| Price/Cash | 0.35 |
| Price/FCF | - |
| Quick Ratio | 4.81 |
| Current Ratio | 4.81 |
| Debt/Equity | 0.05 |
| Return on Assets | -68.09% |
| Return on Equity | -93.54% |
| Return on Investment | -146.95% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 59.12 |
| BETA(β) | 0.21 |
| From 52week Low | 48.35% |
| From 52week High | -79.42% |
| EPS | -1.31 |
| EPS next Year | -0.26 |
| EPS next Qtr | -0.28 |
| EPS this Year | 52.55% |
| EPS next 5 Year | 42.02% |
| EPS past 5 Year | 7.14% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 38.65% |
| Sales Y/Y | - |
| EPS Q/Q | 100.59% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | 100.00% |
| ATR(14) | 0.03 |
| Perf Week | 36.34% |
| Perf Month | 22.61% |
| Perf Quarter | -73.55% |
| Perf Year | -74.19% |
| Perf YTD | -73.55% |
| Target Price | 0.34 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer